Enteropathic Arthropathies

Back

Practice Essentials

The enteropathic arthropathies are a group of rheumatologic conditions that share a link to gastrointestinal (GI) pathology. However, the term typically refers to the inflammatory spondyloarthropathies associated with inflammatory bowel disease (IBD) and to reactive arthritis caused by bacterial (eg, Shigella, Salmonella, Campylobacter, Yersinia, Clostridium difficile) and parasitic (eg, Strongyloides stercoralis, Giardia lamblia, Ascaris lumbricoides, Cryptosporidium species) infections. (See Etiology.)

Psoriatic arthritis, ankylosing spondylitis (AS), and undifferentiated spondyloarthropathy are the other conditions included in the inflammatory spondyloarthropathies that share common clinical and possible etiologic features. (See Etiology, Presentation.)

Other GI conditions with musculoskeletal manifestations include the following:

Complications and prognosis

Complications of enteropathic arthropathy are primarily related to IBD and include the following:

Prognosis depends mainly on the prognosis of the underlying GI disease. Severe spinal inflammatory disease may occur, but this is rare. (See Etiology, Presentation, Treatment, and Medication.)

Etiology

The precise causes of the enteropathic arthropathies are unknown. Inflammation of the GI tract may increase permeability, resulting in absorption of antigenic material, including bacterial antigens. These arthrogenic antigens may then localize in musculoskeletal tissues (including entheses and synovial membrane), thus eliciting an inflammatory response. Alternatively, an autoimmune response may be induced through molecular mimicry, in which the host's immune response to these antigens cross reacts with self-antigens in synovial membrane and other target organs.

Of particular interest is the strong association (80%) between reactive arthritis and human leukocyte antigen (HLA)-B27, an HLA class I molecule. A potentially arthrogenic, bacterially derived antigen peptide could fit in the antigen-presenting groove of the B27 molecule, resulting in a CD8+ T-cell response. HLA-B27 transgenic rats develop features of enteropathic arthropathy with arthritis and gut inflammation.

Sacroiliitis and spondylitis are associated with HLA-B27 (40% and 60%, respectively). HLA-B27 is not associated with peripheral arthritis, with the exception of reactive arthritis.

Epidemiology

Occurrence in the United States

The prevalence of ulcerative colitis (UC) and Crohn disease (CD) is estimated to be 0.05-0.1%, with an increasing incidence for each in the last few decades. While extraintestinal manifestations affecting the skin, eyes, and joints, among other systems, develop in about one quarter of patients with IBD, musculoskeletal manifestations are the most common, with approximately 5-20% of individuals with IBD developing peripheral arthritis and/or spondylitis.

The prevalence of IBD in ankylosing spondylitis (AS) is 5-10%, although up to one third to two thirds of patients with AS have been found through colonoscopy to have subclinical inflammation. Axial involvement occurs more commonly in CD than in UC.

International occurrence

The incidence and prevalence rates for UC and CD in northern and Western Europe are similar to those in the United States, but rates are lower in other regions of the world.

In a systematic review, Ajene and colleagues estimated that the weighted mean global incidence of reactive arthritis with cases of each of the following infections was as follows[1] :

In an Italian study of 269 patients with IBD and joint pain, the prevalence of enteropathic-related spondyloarthritis (ESpA) was 50.5%. ESpA patients showed a peripheral involvement in 53% of cases, axial in 20.6% and peripheral and axial in 26.4% of cases.[2]

Race-, sex-, and age-related demographics

The incidence of IBD is higher in whites, especially those of Ashkenazi Jewish descent, than in other racial groups.

The peripheral arthritis of UC or CD does not have a sex predilection. IBD-associated AS occurs equally in men and women, while idiopathic AS is 2.5 times more common in men.[3] Whipple disease is more common in men, with a male-to-female ratio of 9:1.

IBD is most common in persons aged 15-35 years. Axial involvement in IBD occurs at any age, in contrast to idiopathic AS, which affects men younger than 40 years.

Sofia and colleagues found significant differences in extraintestinal manifestations and disease characteristics between African-American and Caucasian IBD patients in a cross-sectional study of 1235 CD patients and 541 UC patients. African-American CD patients had higher rates of IBD-related arthralgias and surgery and less ileal involvement than Caucasian patients. African-American UC patients were older at diagnosis than Caucasian UC patients and had higher rates of arthralgias and ankylosing spondylitis/sacroiliitis.[4]

History

IBD-associated arthropathies

Axial arthritis (sacroiliitis and spondylitis) in inflammatory bowel disease (IBD) has the following characteristics:

Peripheral arthritis in IBD demonstrates the following characteristics:

Enthesitis affects the following parts of the body:

Extra-articular IBD demonstrates the following characteristics:

Reactive arthritis shows the following characteristics[6] :

Intestinal bypass arthritis demonstrates the following traits:

Celiac sprue demonstrates the following characteristics:

Collagenous and lymphocytic colitis can be characterized as follows:

Whipple disease demonstrates the following characteristics:

Physical Examination

The physical examination should include the following:

Approach Considerations

Lab studies reveal the following:

Although more than 90% of patients with ankylosing spondylitis (AS) alone carry the HLA-B27 gene, it is found in only 30-70% of those with IBD-associated AS. However, nearly all IBD patients with a positive HLA-B27 antigen develop AS.

Anti–Saccharomyces cerevisiae antibodies (ASCA) may be helpful in the diagnosis of inflammatory bowel disease (IBD).[7]

Procedures

Consider arthrocentesis if joint swelling or effusion is present, especially if concern about infection or crystal disease exists.

Consider small-bowel biopsy upon clinical suspicion for Whipple disease or for celiac disease when serology findings are equivocal.

Endoscopy and biopsy may reveal subclinical bowel inflammation in patients with spondyloarthropathy.[8]

Imaging Studies

Radiography

The anteroposterior pelvis or the sacroiliac joints show bilateral sacroiliitis, usually symmetrical when associated with inflammatory bowel disease (IBD). The spine shows syndesmophytes and apophyseal joint involvement. Bamboo spine is uncommon. Erosive disease is uncommon in the peripheral joints, but bony spurs at the heel (enthesitis) may be observed.[9]

MRI

Magnetic resonance imaging (MRI) is useful for early detection of spinal and sacroiliac lesions characteristic of the spondyloarthropathies.

Bone scintigraphy

This study may show increased uptake in a typical pauciarticular, asymmetrical joint pattern.

Ultrasonography

Ultrasonography may be useful in identifying early soft-tissue pathology, such as tenosynovitis.

Approach Considerations

Treatment of inflammatory bowel disease (IBD), including surgery, should always be the initial strategy to induce remission of peripheral arthritis.

Although nonsteroidal anti-inflammatory drugs (NSAIDs) are usually recommended as first-line therapy for spondyloarthropathies, in patients with IBD, these agents may exacerbate GI symptoms.[10] Selection of more cyclooxygenase (COX)-selective NSAIDs may reduce the risk of bowel flares.[11, 12] Corticosteroids may be used systemically or by local injection.

Sulfasalazine (2-3g/day) has been shown to be effective for treatment of the peripheral arthropathy associated with IBD, but not axial disease.[13] While methotrexate can be useful to treat bowel activity in Crohn disease (CD), its effect on joint disease with IBD is less certain.

Although not specifically indicated for an enteropathic arthropathy, the tumor necrosis factor (TNF) antagonists infliximab and adalimumab are indicated to treat ankylosing spondylitis (AS) and IBD, and may be effective for IBD spondyloarthropathy (including axial involvement).[14, 15, 16, 17, 18] Etanercept and golimumab are indicated to treat AS, but neither has been shown to be helpful with bowel disease, and there have been reports of new-onset IBD with these 2 agents.[19]

Whipple disease is treated with long-term tetracycline antibiotics. Celiac disease is treated with a gluten-free diet, although response is not always complete.

Surgical care

Total colectomy or removal of affected colon induces remission of the peripheral arthritis in ulcerative colitis (UC), but not in CD. Surgery provides no benefit for axial involvement in IBD.

Consultations

Consultations with the following specialists can be beneficial:

Diet

A gluten-free diet is used to treat celiac disease.

Activity

Order physical therapy to maintain flexibility, range of motion, and upright posture, especially with axial involvement. Patients must be counseled to continue exercises at home.

Follow-up

Arrange follow-up care with a rheumatologist and gastroenterologist.

Medication Summary

If both bowel and joint disease are active, then agents that target both should be preferred choices. Medications used to manage the enteropathic arthropathies include nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, corticosteroids, second-line agents such as sulfasalazine, and tumor necrosis factor (TNF) antagonists.

The selection of a second-line agents should be left to an experienced rheumatologist or gastroenterologist who is familiar with these agents and the required monitoring.

Corticosteroids may be given orally, intravenously, intramuscularly, or intra-articularly to patients for whom NSAIDs alone are not adequate. Consult with a specialist who is familiar with corticosteroids before prescribing them for specific uses.

Celecoxib (Celebrex)

Clinical Context:  Celecoxib primarily inhibits COX-2. COX-2 is considered an inducible isoenzyme, being induced by pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited; thus, incidence of GI toxicity, such as endoscopic peptic ulcers, bleeding ulcers, perforations, and obstructions, may be decreased when compared with nonselective NSAIDs.

Seek the lowest dose for each patient. Celecoxib has a sulfonamide chain and depends primarily on cytochrome P450 enzymes (which are hepatic enzymes) for metabolism.

Meloxicam (Mobic)

Clinical Context:  Meloxicam decreases the activity of COX, which, in turn, inhibits prostaglandin synthesis. These effects decrease the formation of inflammatory mediators.

Class Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the initial choice of medication to control pain and inflammation related to enteropathic arthropathies. The potential benefits of this class of drugs must be weighed against the possibility that they may exacerbate the underlying GI disease. Several NSAIDs effectively treat this condition, and administration of any one of them is appropriate. Newer cyclooxygenase-2 (COX-2) inhibitors may be less toxic to the GI tract.[13, 14]

Sulfasalazine (Azulfidine)

Clinical Context:  Sulfasalazine has been shown to reduce inflammatory symptoms of ankylosing spondylitis (AS) in controlled studies. The most common toxicities include nausea, dyspepsia, vomiting, diarrhea, and hypersensitivity reactions (rash).

Class Summary

A second-line agent may be considered for articular disease inadequately controlled by nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids or it may be considered as a steroid-sparing agent. Because of their complex toxicities, second-line agents require administration and monitoring by an experienced medical specialist.

Infliximab (Remicade)

Clinical Context:  Infliximab is a chimeric monoclonal antibody. It neutralizes the cytokine TNF-alpha and inhibits its binding to the TNF-alpha receptor. Infliximab has GI indications for fistulous Crohn disease (CD) and ulcerative colitis (UC) and rheumatologic indications for rheumatoid arthritis, psoriatic arthritis (and psoriasis), and AS. It has been shown to be effective for extra-articular manifestations, such as refractory uveitis and pyoderma gangrenosum.

Etanercept (Enbrel)

Clinical Context:  Etanercept is a fusion receptor protein that blocks TNF activity. It inhibits the binding of TNF to cell surface receptors, decreasing inflammatory and immune responses. Etanercept is indicated for AS, psoriatic arthritis, psoriasis, rheumatoid arthritis, and juvenile rheumatoid arthritis.

Adalimumab (Humira)

Clinical Context:  Adalimumab is a recombinant human immunoglobulin-G1 (IgG1) monoclonal antibody specific for human TNF. It is indicated for moderate to severe rheumatoid arthritis, psoriatic arthritis, AS, and CD.

Golimumab (Simponi)

Clinical Context:  Golimumab is a TNF-alpha inhibitor. It decreases inflammation caused by the overproduction of TNF associated with chronic inflammatory diseases. Golimumab is indicated for moderate to severe rheumatoid arthritis, active psoriatic arthritis, and active AS. It is available as the 50 mg/0.5 mL, single-dose Simponi SmartJect (Autoinjector) or as a prefilled syringe.

Class Summary

After nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy, tumor necrosis factor (TNF) inhibitors are uniquely recommended as the next line of treatment for inflammatory spinal disease and enthesopathy, although they can be effective for all aspects of articular disease.[20] Specific agents may vary in their effectiveness against bowel disease activity; furthermore, new-onset inflammatory bowel disease (IBD) has been described in patients with ankylosing spondylitis (AS) who were treated with TNF antagonists.[23, 24]

Author

Pierre Minerva, MD, Consulting Staff, Department of Rheumatology, Bryn Mawr Medical Specialists Association; Consulting Staff, Department of Rheumatology, Bryn Mawr Hospital, Lankenau Hospital, Paoli Hospital

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Disclosure: Nothing to disclose.

Acknowledgements

Lawrence H Brent, MD Associate Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, and American College of Rheumatology

Disclosure: Abbott Honoraria Speaking and teaching; Centocor Consulting fee Consulting; Genentech Grant/research funds Other; HGS/GSK Honoraria Speaking and teaching; Omnicare Consulting fee Consulting; Pfizer Honoraria Speaking and teaching; Roche Speaking and teaching; Savient Honoraria Speaking and teaching; UCB Honoraria Speaking and teaching

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Center for the Advancement of Women's Health and Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians and American College of Rheumatology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr. 2013 Sep. 31(3):299-307. [View Abstract]
  2. Conigliaro P, Chimenti MS, Ascolani M, Triggianese P, Novelli L, Onali S, et al. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev. 2016 Feb. 15 (2):184-90. [View Abstract]
  3. Bourikas LA, Papadakis KA. Musculoskeletal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2009 Dec. 15(12):1915-24. [View Abstract]
  4. Sofia MA, Rubin DT, Hou N, Pekow J. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep. 59(9):2228-35. [View Abstract]
  5. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998 Mar. 42(3):387-91. [View Abstract]
  6. Generali E, Ceribelli A, Massarotti M, Cantarini L, Selmi C. Seronegative reactive spondyloarthritis and the skin. Clin Dermatol. 2015 Sep-Oct. 33 (5):531-7. [View Abstract]
  7. Hoffman IE, Demetter P, Peeters M, et al. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003 May. 62(5):455-9. [View Abstract]
  8. Taddio A, Simonini G, Lionetti P, Lepore L, Martelossi S, Ventura A, et al. Usefulness of wireless capsule endoscopy for detecting inflammatory bowel disease in children presenting with arthropathy. Eur J Pediatr. 2011 Oct. 170(10):1343-7. [View Abstract]
  9. Grigoryan M, Roemer FW, Mohr A, et al. Imaging in spondyloarthropathies. Curr Rheumatol Rep. 2004 Apr. 6(2):102-9. [View Abstract]
  10. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb. 4(2):196-202. [View Abstract]
  11. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb. 4(2):203-11. [View Abstract]
  12. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr. 97(4):910-4. [View Abstract]
  13. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov. 42(11):2325-9. [View Abstract]
  14. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004 Dec. 63(12):1664-9. [View Abstract]
  15. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002 Mar. 46(3):755-65. [View Abstract]
  16. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002 Oct. 97(10):2688-90. [View Abstract]
  17. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005 Aug. 25(6):406-10. [View Abstract]
  18. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007 Nov. 13(11):1424-9. [View Abstract]
  19. Fiehn C, Vay S. Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis. Arthritis Rheum. 2011 Nov. 63(11):3640-1. [View Abstract]
  20. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007 May 15. 57(4):639-47. [View Abstract]
  21. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2001 Dec. 28(12):2667-73. [View Abstract]
  22. Colombo E, Latiano A, Palmieri O, Bossa F, Andriulli A, Annese V. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease?. World J Gastroenterol. 2009 May 28. 15(20):2456-62. [View Abstract]
  23. Karimi O, Pena AS. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease. J Clin Gastroenterol. 2008 Sep. 42 Suppl 3 Pt 1:S136-41. [View Abstract]
  24. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011 Apr. 7(4):235-41. [View Abstract]
  25. Mielants H, Veys EM. Enteropathic arthropathis. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 4th. Mosby Elsevier; 2008. 1189-1195 / 113.
  26. Palm O, Moum B, Jahnsen J, et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based sudy (the IBSEN study). Rheumatology. 2001. 40:1256-1261.
  27. Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011 Apr. 341(4):284-6. [View Abstract]
  28. Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005 Jun. 118(6):592-603. [View Abstract]
  29. Wollheim FA. Enteropathic arthritis: how do the joints talk with the gut?. Curr Opin Rheumatol. 2001 Jul. 13(4):305-9. [View Abstract]